Search Results

Your search matched 2 results


What Biogen’s Alzheimer’s Drug Approval Means for Life Sciences Companies | Blog

In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.


A New Drug Price Deal Signals Significant Policy Shift | Blog

This month policies aimed at lowering drug prices are back on the table.